Advertisement
Advertisement
RZLT
Rezolute, Inc. Common Stock (NV)
4.02
USDSponsored
+0.15
+3.88%
Nov 10, 15:59 UTC -5
Closed
After-Market
4.11
+0.09
+2.24%
Rezolute, Inc. Common Stock (NV) (RZLT) Earnings
RZLT Earnings Reports
Positive Surprise Ratio
RZLT beat 19 of 30 last estimates.
63%
Next Report
Date of Next Report
Feb 10, 2027
Estimate for Q2 27 (Revenue/ EPS)
--
/-$0.17
Implied change from Q1 27 (Revenue/ EPS)
--
/-5.56%
Implied change from Q2 26 (Revenue/ EPS)
--
/-22.73%
Rezolute, Inc. Common Stock (NV) earnings per share and revenue
On Nov 05, 2026, RZLT reported earnings of -0.18 USD per share (EPS) for Q1 27, beating the estimate of -0.18 USD, resulting in a 4.61% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.59% price change (close before vs. close after earnings).
Looking ahead to Q2 27, -- analysts forecast an EPS of -0.17 USD, with revenue projected to reach -- USD, implying an decrease of -5.56% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Rezolute, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Rezolute, Inc. Common Stock (NV) reported EPS of -$0.18, beating estimates by 4.61%, and revenue of $0.00, 0% as expectations.
How did the market react to Rezolute, Inc. Common Stock (NV)'s Q1 2027 earnings?
The stock price moved up 6.59%, changed from $3.64 before the earnings release to $3.88 the day after.
When is Rezolute, Inc. Common Stock (NV) expected to report next?
The next earning report is scheduled for Feb 10, 2027.
What are the forecasts for Rezolute, Inc. Common Stock (NV)'s next earnings report?
Based on --
analysts, Rezolute, Inc. Common Stock (NV) is expected to report EPS of -$0.17 and revenue of -- for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.